Enanta Pharmaceuticals
Update in progressENTA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for virology and immunology. Its pipeline includes EDP-514 for chronic HBV infection in phase 1b; zelicapavir and EDP-323 in phase II for RSV; EDP-235 in phase II for human coronaviruses; EDP-978 for chronic spontaneous urticaria; glecaprevir for hepatitis C; and EPS-3903 for atopic dermatitis. It collaborates with Abbott to develop HCV protease inhibitors like paritaprevir and glecaprevir. Founded in 1995, based in Watertown, MA.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Jay R. Luly Ph.D.
- Founded1995
- Employees120
- Websitewww.enanta.com
Identifiers
- ISINUS29251M1062
- FIGIBBG001V9NSB4
- LEI529900SSN4DODDQSN594
- CUSIP29251M106
- CIK0001177648